Many potentially efficient drugs have been created to treat neurological disorders, but they cannot be used in practice.
Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain. For this reason, the team of researchers led by Christophe Bernard at Inserm Unit 1106, “Institute of Systems Neuroscience” (INS), with the help of scientists at the École des Mines de Saint-Étienne and Linköping University (Sweden) have developed an organic electronic micropump which, when combined with an anticonvulsant drug, enables localised inhibition of epileptic seizure in brain tissue in vitro. This research is published in the journal Advanced Materials.
Drugs constitute the most widely used approach for treating brain disorders. However, many promising drugs failed during clinical testing for several reasons:
- they are diluted in potentially toxic solutions,
- they may themselves be toxic when they reach organs to which they were not initially directed,
- the blood-brain barrier, which separates the brain from the blood circulation, prevents most drugs from reaching their targets in the brain,
- drugs that succeed in penetrating the brain will act in a non-specific manner, i.e. on healthy regions of the brain, altering their functions.
Epilepsy is a typical example of a condition for which many drugs could not be commercialised because of their harmful effects, when they might have been effective for treating patients resistant to conventional treatments [1].
During an epileptic seizure, the nerve cells in a specific area of the brain are suddenly activated in an excessive manner. How can this phenomenon be controlled without affecting healthy brain regions? To answer this question, Christophe Bernard’s team, in collaboration with a team led by George Malliaras at the Georges Charpak-Provence Campus of the École des Mines of Saint-Étienne and Swedish scientists led by Magnus Berggren from Linköping University, have developed a biocompatible micropump that makes it possible to deliver therapeutic substances directly to the relevant areas of the brain.
The micropump (20 times thinner than a hair) is composed of a membrane known as “cation exchange,” i.e., it has negative ions attached to its surface. It thus attracts small positively charged molecules, whether these are ions or drugs. When an electrical current is applied to it, the flow of electrons generated projects the molecules of interest toward the target area.
Read more: An electronic micropump to deliver treatments deep within the brain
The Latest on: Drug delivery system
[google_news title=”” keyword=”Drug delivery system” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug delivery system
- Scientists learn from caterpillars how to create self-assembling capsules for drug deliveryon April 26, 2024 at 8:00 am
Self-assembling molecules that spontaneously organize themselves to form complex structures are common in nature. For example, the tough outer layer of insects, called the cuticle, is rich in proteins ...
- Drug Delivery Technologies market is projected to grow at a CAGR of 5.5% by 2034: Visiongainon April 25, 2024 at 11:16 pm
Visiongain has published a new report entitled Drug Delivery Technologies Market Report 2024-2034: Forecasts by Route of Administration (Implantable Drug Delivery, Injectable Drug Delivery Nasal Drug ...
- Learning from caterpillars to create self-assembling capsules for drug deliveryon April 25, 2024 at 5:00 pm
“To the best of our knowledge, this is the first time that peptide nanocapsules have been created without templates, paving the way for a customisable drug delivery system,” said Assoc Prof Yu. “Our ...
- Study highlights benefits of automated insulin delivery for children in UKon April 25, 2024 at 6:44 am
A study in the UK demonstrated significant improvements in HbA1c for users of automated insulin delivery technologies.
- Global Injectable Drug Delivery Market Set to Soar, Reaching US$ 113.87 Billion by 2034on April 24, 2024 at 9:57 pm
Injectable Drug Delivery Market is expected to reach an impressive US$ 113.87 billion by the end of 2034, at a CAGR of 8.70%.
- MIT Develops Closed-Loop Drug Delivery System to Enhance Chemotherapyon April 24, 2024 at 5:37 pm
When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient’s body surface area. This is estimated by plugging the patient’s height and weight into an equation ...
- A closed-loop drug-delivery system could improve chemotherapyon April 24, 2024 at 2:02 pm
When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient's body surface area. This is estimated by plugging the patient's height and weight into an equation ...
- Sanofi gets grant for optical decoding system for determining medicament dose in drug delivery deviceon April 24, 2024 at 6:18 am
Enhance medication dosing accuracy with Sanofi's patented optical decoding system for drug delivery devices. Improve efficiency and precision in dispensing with this innovative technology.
- Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid Systemon April 24, 2024 at 12:16 am
Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to reach their desired targets. Glysious ...
- Injectable Drug Delivery Market To Reach USD 1,714.8 Billion By 2032, Says DataHorizzon Researchon April 22, 2024 at 10:30 pm
The Injectable Drug Delivery market size was valued at USD 668.2 Billion in 2023 and is expected to reach a market size of USD 1,714.8 Billion by 2032 at a CAGR of 11.1%.Fort Collins, Colorado, April ...
via Bing News